GenomeDx Biosciences

Uro Pipeline: FDA accepts two supplemental applications for mUC agentOther pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.
Biomarkers predict metastasis, biochemical recurrenceClinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
Markers redefining prostate cancer careIn this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
Data support PCa markers, but more study neededA leader in urologic oncology discusses four currently available molecular tests in this report from Urology Times SUO internship program member Brandon Manley, MD.
Epigenetics and genetics: The future of cost-effective care?The purpose of this article is to provide a clear understanding of the basis for the genetic and epigenetic tools that are increasingly used in medicine, highlight some of these tools currently used in urology, and explain the clinical and medicolegal ramifications of direct-to-consumer tests.
Biomarkers offer insight into PCa racial disparityA newly identified subset of prostate cancer biomarkers could help explain why African-American men are more likely than European-American men to develop and die from prostate cancer.
Medicare to cover another prostate Ca testPalmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier, developer GenomeDx Biosciences reported.
PCa test predicts aggressiveness, influences treatmentThe Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.
PCa test predicts aggressiveness, influences treatmentThe Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.